The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment. Read more about The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment.
20th anniversary of the WHO Framework Convention on Tobacco Control coming into force: time for a step change in ambition. Read more about 20th anniversary of the WHO Framework Convention on Tobacco Control coming into force: time for a step change in ambition.
Predatory journals: what can we do to protect their prey? Read more about Predatory journals: what can we do to protect their prey?
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial. Read more about Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial.
Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial. Read more about Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial.
IL-23 inhibition for chronic inflammatory disease. Read more about IL-23 inhibition for chronic inflammatory disease.
Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply. Read more about Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply.
Preventing generalised pustular psoriasis. Read more about Preventing generalised pustular psoriasis.
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Read more about Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Reducing the risks of nuclear war-the role of health professionals. Read more about Reducing the risks of nuclear war-the role of health professionals.
